CD44 and lymphoma: A recent study by the group of Clemens Schmitt showed that the chemotherapeutic Adriamycin (Doxorubicin) induced senescence in mouse lymphoma cells and that these senescent lymphoma cells expressed stem cell markers such as CD133 or CD44.